Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulconazole is a synthetic imidazole antifungal agent used topically to treat superficial fungal infections of the skin, including tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor (pityriasis versicolor)[1][3][4][5]. It is available as a cream or solution for topical application. The drug works by inhibiting lanosterol 14-alpha demethylase, a cytochrome P-450-dependent enzyme in fungi that is essential for converting lanosterol to ergosterol—a key component of the fungal cell membrane[4][6]. Inhibition of this enzyme disrupts ergosterol synthesis, leading to increased cellular permeability and ultimately fungal cell death[6][8]. Sulconazole was first approved in 1985 and is considered effective and well-tolerated for superficial mycoses[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulconazole.